Invokana Dosage

Medically reviewed by Drugs.com. Last updated on July 31, 2020.

Generic name: canagliflozin 100mg
Dosage form: tablet, film coated

Prior to Initiation of INVOKANA

Assess renal function before initiating INVOKANA and periodically thereafter [see Warnings and Precautions (5.4)].

In patients with volume depletion not previously treated with canagliflozin, normalize volume status before initiating INVOKANA [see Warnings and Precautions (5.2), Use in Specific Populations (8.5, 8.6)].

Recommended Dosage

See Table 1 for dosage recommendations based on estimated glomerular filtration rate (eGFR). There are insufficient data to support dosing recommendations for initiation of therapy in patients with an eGFR < 30 mL/min/1.73 m2 with albuminuria greater than 300 mg/day or in patients with an eGFR < 45 mL/min/1.73 m2 with albuminuria less than or equal to 300 mg/day. In patients already initiated on therapy who meet the criterion of an eGFR < 30 mL/min/1.73 m2 with albuminuria greater than 300 mg/day, therapy can be continued at 100 mg once daily [see Use in Specific Populations (8.6) and Clinical Studies (14.3)].

Table 1: Recommended Dosage
estimated glomerular filtration rate eGFR (mL/min/1.73 m2)	Recommended Dosage
* with albuminuria >300 mg/day.
eGFR ≥ 60	100 mg orally once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily for additional glycemic control.
eGFR 45 to < 60	100 mg once daily.
eGFR 30 to < 45*	100 mg once daily.
On dialysis	Contraindicated [see Contraindications].

Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers

Patients with eGFR 60 mL/min/1.73 m2 or greater

If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA 100 mg. The dose may be increased to 300 mg once daily in patients currently tolerating INVOKANA 200 mg and who require additional glycemic control [see Drug Interactions (7.1)].

Patients with eGFR less than 60 mL/min/1.73 m2

If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA 100 mg. Consider adding another antihyperglycemic agent in patients who require additional glycemic control.